Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), retaining the price target of $35.00.

Emily Bodnar’s rating is based on MiNK Therapeutics’ promising clinical data and strategic advancements. The company has shown encouraging initial efficacy data from its Phase 2 study of agenT-797 for gastric cancer, with notable increases in immune cell activity and pro-inflammatory cytokines after treatment. This suggests potential therapeutic benefits, although more comprehensive data is expected in the second half of 2025 to confirm these findings.
Additionally, MiNK’s strategic move to initiate an externally funded Phase 1 study for graft versus host disease (GvHD) is seen as a positive step. This study, supported by NIAID funding, allows the company to explore new indications without depleting its own resources. The combination of these factors, including the potential for long-term patient follow-up data, underpins the Buy rating given by Emily Bodnar.

Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, AnaptysBio, and Jasper Therapeutics. According to TipRanks, Bodnar has an average return of -4.6% and a 28.52% success rate on recommended stocks.